Changes to This Summary (05/03/2013)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Cellular Classification and Biologic Correlates

Added text to state that a comprehensive review of nodular lymphocyte-predominant Hodgkin lymphoma addressing biology, evaluation, and treatment has been published (cited Shankar et al. as reference 16).

Added Appel et al. as reference 22.

Treatment for Newly Diagnosed Children and Adolescents with Hodgkin Lymphoma

Added text to state that in one trial of 52 nodular lymphocyte-predominant Hodgkin lymphoma patients who were treated with chemotherapy alone, the 5-year event-free survival was 96% (cited Appel et al. as reference 23 and level of evidence 1iiDi). Also added Shankar et al. as reference 26.

Added text to state that a summary of treatment approaches for nodular lymphocyte-predominant Hodgkin lymphoma can be found in Table 8.

Added text to state that adjuvant radiation therapy may be associated with excess late effects or mortality (cited Yeh et al. as reference 36).

Added Tebbi et al. as reference 43.

Revised Table 4 to include the CVP regimen (cyclophosphamide, vinblastine, and prednisone) as a contemporary chemotherapy regimen for children and adolescents with Hodgkin lymphoma (cited Shankar et al. as reference 45).

Added text to state that children and adolescents with low-risk Hodgkin lymphoma treated with involved-field radiation therapy (IFRT) after complete response to two cycles of DBVE (doxorubicin, bleomycin, vincristine, and etoposide) had outcomes comparable to those treated with four cycles of DBVE and IFRT; this response-dependent approach permitted reduction in chemotherapy exposure in 45% of patients.

Added Nodular lymphocyte-predominant Hodgkin lymphoma as a new subsection.

Treatment of Primary Refractory/Recurrent Hodgkin Lymphoma in Children and Adolescents

Added Treatment Options Under Clinical Evaluation as a new subsection.

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.